News

Fish Oil Cuts Heart Failure Morbidity, Mortality


 

Nevertheless, he added, there remains “a bit of mystery” regarding the mechanism of benefit, as there was no significant reduction in sudden cardiac death or presumed arrhythmic death in the n-3 PUFA group. And the optimal dosage has yet to be defined, Dr. Komajda said.

GISSI-HF was simultaneously published online (Lancet 2008 Aug. 31 [doi:10.1016/50140–6736(08)61239–8]).

The trial was funded by the Società Prodotti Antibiotici S.p.A., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., and AstraZeneca Pharmaceuticals, which provided Dr. Tavazzi with research support and honoraria.

There was a significant adjusted 9% relative risk reduction in the n-3 PUFA group. DR. TAVAZZI

Pages

Recommended Reading

Extra ICD Shocks May Be Harmful to Health
MDedge Internal Medicine
Atherectomy for Limb Ischemia Has Good Results
MDedge Internal Medicine
A-Fib Affects Quality of Life of Patient and Spouse Equally
MDedge Internal Medicine
Less A-Fib Seen With Statins In Postmenopausal Women
MDedge Internal Medicine
Tissue Doppler Imaging Identifies Heart Failure Risk
MDedge Internal Medicine
Major CV Events Not Decreased With Vytorin
MDedge Internal Medicine
Omega-3 Fatty Acid Cuts Rate of New Atrial Fib
MDedge Internal Medicine
Low Serum Selenium Boosts Hypertension Risk
MDedge Internal Medicine
Proper Antihypertensive Prescribing Prompted by Computerized Reminders
MDedge Internal Medicine
Obesity Alters Normal Nocturnal BP Patterns
MDedge Internal Medicine